Form 4: ADMA Biologics Director Jerrold Grossman Reports Stock and Option Transactions

Director Jerrold Grossman reports acquisition of ADMA Biologics stock and stock options, along with details of beneficial ownership.

Summary

• On February 26, 2024, Jerrold B. Grossman, a director of ADMA Biologics, reported the acquisition of 24,040 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs will vest in two equal installments over six and twelve months from the grant date.
• Grossman also acquired 37,541 stock options with an exercise price of $5.40, vesting monthly over one year and expiring on February 26, 2034.
• Following these transactions, Grossman directly owns 467,305 shares of common stock, including the newly granted RSUs.
• Grossman also has indirect ownership through Brookwood LLC (22,857 shares), the Jerrold Grossman 2019 Irrevocable Trust (31,381 shares), Genesis Foundation Inc. (38,294 shares), and shares owned by his wife (175 shares).

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of insider transactions. The acquisition of shares and options suggests a positive outlook from the director, but it's not a strong indicator.

Positives

• The acquisition of stock and options by a director signals confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The reported transactions provide shareholders with insight into the actions of a company director.

Key Dates